Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly Plans New Outcomes Study to Expand Jardiance Label

by Zacks Equity Research

Eli Lilly and Company (LLY) along with partner Boehringer Ingelheim are planning to conduct a new outcomes study to evaluate the type II diabetes drug Jardiance (empagliflozin) for treatment of patients with chronic kidney disease.

    Novartis Presents Positive Data on CAR-T Cell Therapy Drug

    by Zacks Equity Research

    Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.

      Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M

      by Zacks Equity Research

      Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.

        J&J Announces EU Regulatory Approval for Actelion Deal

        by Zacks Equity Research

        Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.

          Alkermes Commences Phase III Study for Schizophrenia Drug

          by Zacks Equity Research

          Alkermes plc (ALKS) announced that it initiated a phase III study, ENLIGHTEN-Early on experimental candidate, ALKS 3831.

            Endo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down

            by Zacks Equity Research

            Endo International plc (ENDP) received a huge setback when the FDA directed the company to voluntarily remove its opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market over abuse concerns.

              Why AnaptysBio (ANAB) Could Be Positioned for a Slump

              by Zacks Equity Research

              One stock that you may want to consider dropping is AnaptysBio, Inc. (ANAB), which has witnessed a significant price decline in the past four weeks

                Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises

                by Zacks Equity Research

                Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus.

                  Adamas Provides Positive Long-term Data on Parkinson's Drug

                  by Zacks Equity Research

                  Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

                    Should You Get Rid of Miragen Therapeutics (MGEN) Now?

                    by Zacks Equity Research

                    Miragen Therapeutics (MGEN) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

                      Mallinckrodt (MNK) Commences Phase III Study of StrataGraft

                      by Zacks Equity Research

                      Mallinckrodt plc (MNK) has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.

                        AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

                        by Zacks Equity Research

                        AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

                          Acorda Presents Phase III Data on PD Candidate CVT-301

                          by Zacks Equity Research

                          Acorda Therapeutics, Inc. (ACOR) presented data from a phase III study SPAN-PD, evaluating its late stage candidate CVT-301 (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS).

                            Alkermes Gets FDA Nod for Two Month Dose of Aristada

                            by Zacks Equity Research

                            Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.

                              Jazz Pharma Sleep Disorder Candidate Positive in Phase III

                              by Zacks Equity Research

                              Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy results from studies evaluating its lead pipeline candidate, JZP-110, in adult patients with excessive sleepiness (ES) associated with narcolepsy and obstructive sleep apnea (OSA).

                                Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.

                                by Zacks Equity Research

                                Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).

                                  Novartis' (NVS) Tasigna Receives Label Update Nod in EU

                                  by Zacks Equity Research

                                  Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.

                                    Celgene and Agios Announce Data on Idhifa for Leukemia

                                    by Zacks Equity Research

                                    Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).

                                      Roche Announces Data on Perjeta, Alecensa and Tecentriq

                                      by Zacks Equity Research

                                      Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.

                                        Seattle Genetics Reports Updated Results on Cancer Drug

                                        by Zacks Equity Research

                                        Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME).

                                          Kite Pharma (KITE) Releases Data on Lead Drug for Leukemia

                                          by Zacks Equity Research

                                          Kite Pharma, Inc. (KITE) announced results from phase I trial, ZUMA-3, on lead candidateKTE-C19 (axicabtagene ciloleucel) in adults with high burden relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

                                            Amgen Files for Repatha in the U.S., EU for Expanded Use

                                            by Zacks Equity Research

                                            Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

                                              Zacks.com featured highlights: VIVUS, Diversified Restaurant Holdings, Qumu, MiX Telematics and Aerohive Networks

                                              by Zacks Equity Research

                                              Zacks.com featured highlights: VIVUS, Diversified Restaurant Holdings, Qumu, MiX Telematics and Aerohive Networks

                                                Dynavax (DVAX) Looks Good: Stock Gains 16.9% in Session

                                                by Zacks Equity Research

                                                Dynavax Technologies Corporation (DVAX) moved big last session, as its shares rose almost 17% on the day.

                                                  VIVUS (VVUS) Shares March Higher, Can It Continue?

                                                  by Zacks Equity Research

                                                  As of late, it has definitely been a great time to be an investor in VIVUS, Inc. (VVUS).